Teckro Expands Leadership Team

News
July 02, 2019

Founders Fund-backed company announces 5 senior hires with domain experience from publicly traded companies including Veeva Systems, Salesforce, ICON and Munich Re

Teckro, the company transforming clinical trials for the world’s leading pharmaceutical and emerging biotech firms, today announced five significant appointments to its leadership team as it executes aggressive go-to-market and product strategies.

The hires follow Teckro’s Series C funding announcement in February, featuring investment from major US venture capital firms, including Founders Fund, Bill Maris’ Section 32, Borealis Ventures, Northpond Ventures and Sands Capital Ventures. To date, Teckro has raised $43 million, with the latest round of $25 million earmarked for scale-up activities to accelerate growth and meet a sharp increase in demand from pharmaceutical and biotech companies looking to simplify and modernize clinical trials with Teckro.

Speaking on the appointments to the leadership team, Teckro CEO and co-founder Gary Hughes said, “Every clinical trial starts with a question. At Teckro, we believe that finding answers should be simple for all study stakeholders anytime, anywhere. The new leadership appointments are important as we continue to expand our product and commercial strategies. I am delighted to have this group of seasoned professionals from established public companies join Teckro on our mission to simplify and modernize clinical research.”

Teckro’s new hires bring vast experience across domains, including medical affairs, commercial and engineering:

Professor Brendan Buckley, Chief Medical Officer
With more than four decades in academic clinical practice, Buckley brings extensive experience as a senior clinical investigator. Buckley has served in several independent regulatory roles in the European Medicines Agency (EMA) and the Irish competent authority. With more than 150 scientific papers published, Buckley also authored the recent opinion-leading book Re-Engineering Clinical Trials. From 2011-2017, Buckley served as Chief Medical Officer and Executive Vice President of ICON, one of the world’s largest clinical research organizations.

Kelly Brown, Chief Marketing Officer and Sandra Blaser, VP of Services & Success
Also joining Teckro from global life science software giant Veeva Systems are Kelly Brown and Sandra Blaser as Chief Marketing Officer and Vice President of Services & Success, respectively. Brown, previously VP of Marketing in Europe at Veeva, brings more than a decade of experience in the technology sector, including an 11-year stint at EMC (now Dell EMC). Early in her career, Blaser was one of first European employees at Salesforce and served as its first-ever customer success manager in the region. Before joining Teckro, Blaser spent more than five years at Veeva where she managed the customer success team in Europe.

Anita Callan, VP of Product and Neil Flanagan, VP of Engineering
On the technical side, Teckro bolsters its team with two seasoned professionals, Anita Callan and Neil Flanagan, who collectively will use their vast experience to ensure Teckro’s products meet and exceed customer expectations. Callan joins as Vice President of Product, most recently working at Aer Lingus where she held product and content strategy positions. Flanagan joins as Teckro Vice President of Engineering with extensive experience in building and running highly scalable technology teams. Prior to Teckro, Flanagan most recently was Head of Digital Operations at Munich Re, one of the world’s largest reinsurance companies.

Collectively, these new leaders are instrumental in Teckro’s mission to simplify and modernize clinical research. Demand is strong as the number of trials on Teckro has more than tripled over the past couple of years. Today, more than active 11,800 study sites use Teckro in all major countries around the world. Equally important, user adoption of Teckro is high, with more than 90% of registered users active on the platform.